Table X-1
KAPOSI'S SARCOMA

NUMBER OF CASES
By SEER Location and Year of Diagnosis, 1975-2002
All Races, Males, All Ages

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SEER 9</td>
<td>59</td>
<td>55</td>
<td>55</td>
<td>153</td>
<td>589</td>
<td>1241</td>
<td>1877</td>
<td>2235</td>
<td>2222</td>
<td>1949</td>
<td>1411</td>
<td>467</td>
<td>391</td>
<td>354</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SEER 9 except</td>
<td>45</td>
<td>41</td>
<td>39</td>
<td>56</td>
<td>159</td>
<td>349</td>
<td>587</td>
<td>848</td>
<td>910</td>
<td>925</td>
<td>743</td>
<td>276</td>
<td>246</td>
<td>242</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SF-Oakland</td>
<td>14</td>
<td>14</td>
<td>16</td>
<td>97</td>
<td>430</td>
<td>892</td>
<td>1290</td>
<td>1387</td>
<td>1312</td>
<td>1024</td>
<td>668</td>
<td>191</td>
<td>145</td>
<td>112</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>San Francisco-Oakland SMSA (^b)</td>
<td>14</td>
<td>14</td>
<td>16</td>
<td>97</td>
<td>430</td>
<td>892</td>
<td>1290</td>
<td>1387</td>
<td>1312</td>
<td>1024</td>
<td>668</td>
<td>191</td>
<td>145</td>
<td>112</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>San Francisco City/County</td>
<td>7</td>
<td>7</td>
<td>8</td>
<td>75</td>
<td>366</td>
<td>755</td>
<td>1063</td>
<td>1068</td>
<td>1002</td>
<td>750</td>
<td>486</td>
<td>121</td>
<td>84</td>
<td>70</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AGE-ADJUSTED CANCER INCIDENCE RATES\(^a\)
By SEER Location and Year of Diagnosis, 1975-2002
All Races, Males, All Ages

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SEER 9</td>
<td>0.5</td>
<td>0.4</td>
<td>0.4</td>
<td>0.9</td>
<td>2.9</td>
<td>5.7</td>
<td>8.3</td>
<td>9.5</td>
<td>9.1</td>
<td>7.6</td>
<td>5.4</td>
<td>1.8</td>
<td>1.5</td>
<td>1.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SEER 9 except</td>
<td>0.5</td>
<td>0.4</td>
<td>0.4</td>
<td>0.5</td>
<td>1.0</td>
<td>2.0</td>
<td>3.1</td>
<td>4.3</td>
<td>4.4</td>
<td>4.3</td>
<td>3.4</td>
<td>1.3</td>
<td>1.1</td>
<td>1.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SF-Oakland</td>
<td>0.7</td>
<td>0.7</td>
<td>0.8</td>
<td>3.0</td>
<td>12.1</td>
<td>23.7</td>
<td>33.0</td>
<td>34.2</td>
<td>31.8</td>
<td>24.2</td>
<td>15.8</td>
<td>4.6</td>
<td>3.3</td>
<td>2.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>San Francisco-Oakland SMSA (^b)</td>
<td>0.7</td>
<td>0.7</td>
<td>0.8</td>
<td>3.0</td>
<td>12.1</td>
<td>23.7</td>
<td>33.0</td>
<td>34.2</td>
<td>31.8</td>
<td>24.2</td>
<td>15.8</td>
<td>4.6</td>
<td>3.3</td>
<td>2.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>San Francisco City/County</td>
<td>1.3</td>
<td>1.2</td>
<td>1.3</td>
<td>10.0</td>
<td>44.7</td>
<td>89.2</td>
<td>122.8</td>
<td>123.8</td>
<td>114.6</td>
<td>83.9</td>
<td>54.4</td>
<td>13.1</td>
<td>9.1</td>
<td>7.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) Rates are per 100,000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
\(^b\) The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Kaposi's Sarcoma.

---
Table X-2

KAPOSI'S SARCOMA

NUMBER OF CASES
By SEER Location and Year of Diagnosis, 1975-2002
All Races, Males, Ages 20-54

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1976</td>
<td>SEER 9</td>
<td>6</td>
<td>6</td>
<td>7</td>
<td>95</td>
<td>509</td>
<td>1160</td>
<td>1752</td>
<td>2107</td>
<td>2074</td>
<td>1838</td>
<td>1291</td>
<td>396</td>
<td>325</td>
</tr>
<tr>
<td>1978</td>
<td>SEER 9 except</td>
<td>6</td>
<td>5</td>
<td>&lt;4</td>
<td>13</td>
<td>106</td>
<td>302</td>
<td>517</td>
<td>774</td>
<td>843</td>
<td>868</td>
<td>670</td>
<td>229</td>
<td>201</td>
</tr>
<tr>
<td>SF-Oakland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1980</td>
<td>San Francisco-</td>
<td>0</td>
<td>&lt;4</td>
<td>6</td>
<td>82</td>
<td>403</td>
<td>858</td>
<td>1235</td>
<td>1333</td>
<td>1231</td>
<td>970</td>
<td>621</td>
<td>167</td>
<td>124</td>
</tr>
<tr>
<td>Oakland SMSA b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1982</td>
<td>San Francisco-</td>
<td>0</td>
<td>&lt;4</td>
<td>5</td>
<td>72</td>
<td>353</td>
<td>729</td>
<td>1026</td>
<td>1035</td>
<td>949</td>
<td>715</td>
<td>455</td>
<td>112</td>
<td>76</td>
</tr>
<tr>
<td>City/County</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AGE-ADJUSTED CANCER INCIDENCE RATES a
By SEER Location and Year of Diagnosis, 1975-2002
All Races, Males, Ages 20-54

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1976</td>
<td>SEER 9</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.9</td>
<td>4.7</td>
<td>10.5</td>
<td>15.1</td>
<td>17.5</td>
<td>16.5</td>
<td>14.1</td>
<td>9.6</td>
<td>2.9</td>
<td>2.4</td>
</tr>
<tr>
<td>1978</td>
<td>SEER 9 except</td>
<td>0.1</td>
<td>0.1</td>
<td>–</td>
<td>0.1</td>
<td>1.2</td>
<td>3.2</td>
<td>5.2</td>
<td>7.5</td>
<td>7.9</td>
<td>7.8</td>
<td>5.9</td>
<td>2.0</td>
<td>1.7</td>
</tr>
<tr>
<td>SF-Oakland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1980</td>
<td>San Francisco-</td>
<td>0.0</td>
<td>–</td>
<td>0.4</td>
<td>4.8</td>
<td>21.9</td>
<td>45.3</td>
<td>62.6</td>
<td>64.9</td>
<td>58.1</td>
<td>45.0</td>
<td>28.7</td>
<td>7.5</td>
<td>5.4</td>
</tr>
<tr>
<td>Oakland SMSA b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1982</td>
<td>San Francisco-</td>
<td>0.0</td>
<td>–</td>
<td>1.5</td>
<td>19.3</td>
<td>85.7</td>
<td>171.2</td>
<td>235.6</td>
<td>238.1</td>
<td>213.2</td>
<td>157.8</td>
<td>99.5</td>
<td>23.8</td>
<td>16.1</td>
</tr>
<tr>
<td>City/County</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a Rates are per 100,000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
b The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Kaposi's Sarcoma.
- Statistic not shown. Rate based on less than 4 cases for the time interval.
Table X-3

KAPOSI'S SARCOMA

NUMBER OF CASES
By SEER Location and Year of Diagnosis, 1975-2002
All Races, Males, Ages 55+

Year of Diagnosis

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>SEER 9</td>
<td>53</td>
<td>49</td>
<td>48</td>
<td>58</td>
<td>78</td>
<td>80</td>
<td>123</td>
<td>127</td>
<td>147</td>
<td>111</td>
<td>120</td>
</tr>
<tr>
<td>SEER 9 except SF-Oakland</td>
<td>39</td>
<td>36</td>
<td>38</td>
<td>43</td>
<td>52</td>
<td>47</td>
<td>70</td>
<td>74</td>
<td>66</td>
<td>57</td>
<td>73</td>
</tr>
<tr>
<td>San Francisco-Oakland SMSA</td>
<td>14</td>
<td>13</td>
<td>10</td>
<td>15</td>
<td>26</td>
<td>33</td>
<td>53</td>
<td>53</td>
<td>81</td>
<td>54</td>
<td>47</td>
</tr>
<tr>
<td>San Francisco City/County</td>
<td>7</td>
<td>6</td>
<td>&lt;4</td>
<td>&lt;4</td>
<td>13</td>
<td>26</td>
<td>37</td>
<td>32</td>
<td>53</td>
<td>35</td>
<td>31</td>
</tr>
</tbody>
</table>

AGE-ADJUSTED CANCER INCIDENCE RATES*
By SEER Location and Year of Diagnosis, 1975-2002
All Races, Males, Ages 55+

Year of Diagnosis

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>SEER 9</td>
<td>2.2</td>
<td>1.9</td>
<td>1.8</td>
<td>2.0</td>
<td>2.5</td>
<td>2.3</td>
<td>3.3</td>
<td>3.4</td>
<td>3.9</td>
<td>2.7</td>
<td>2.9</td>
</tr>
<tr>
<td>SEER 9 except SF-Oakland</td>
<td>2.0</td>
<td>1.6</td>
<td>1.7</td>
<td>1.8</td>
<td>1.9</td>
<td>1.8</td>
<td>2.4</td>
<td>2.5</td>
<td>2.2</td>
<td>1.7</td>
<td>2.2</td>
</tr>
<tr>
<td>San Francisco-Oakland SMSA</td>
<td>3.4</td>
<td>3.2</td>
<td>2.6</td>
<td>2.8</td>
<td>5.4</td>
<td>4.9</td>
<td>7.7</td>
<td>8.1</td>
<td>12.8</td>
<td>8.0</td>
<td>6.9</td>
</tr>
<tr>
<td>San Francisco City/County</td>
<td>5.9</td>
<td>4.6</td>
<td>-</td>
<td>-</td>
<td>9.1</td>
<td>17.1</td>
<td>23.8</td>
<td>21.9</td>
<td>37.8</td>
<td>24.0</td>
<td>21.7</td>
</tr>
</tbody>
</table>

* Rates are per 100,000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

** The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Kaposi's Sarcoma.

---

Statistic not shown. Rate based on less than 4 cases for the time interval.
<table>
<thead>
<tr>
<th>AGE-ADJUSTED RATES</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Males</td>
<td>Females</td>
<td>Males</td>
</tr>
<tr>
<td>YEAR OF DIAGNOSIS:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1975</td>
<td>0.2</td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>1976</td>
<td>0.2</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>1977</td>
<td>0.3</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>1978</td>
<td>0.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1979</td>
<td>0.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1980</td>
<td>0.3</td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>1981</td>
<td>0.3</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>1982</td>
<td>0.7</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>1983</td>
<td>1.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1984</td>
<td>1.8</td>
<td>3.6</td>
<td></td>
</tr>
<tr>
<td>1985</td>
<td>2.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1986</td>
<td>3.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1987</td>
<td>3.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1988</td>
<td>4.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1989</td>
<td>4.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1990</td>
<td>4.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1991</td>
<td>4.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1992</td>
<td>4.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1993</td>
<td>3.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1994</td>
<td>3.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1995</td>
<td>3.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1996</td>
<td>2.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1997</td>
<td>1.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1998</td>
<td>0.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1999</td>
<td>0.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td>0.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td>0.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td>0.7</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AGE-ADJUSTED RATES, 1998-2002

<table>
<thead>
<tr>
<th>AGE AT DIAGNOSIS:</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All ages</td>
<td>0.8</td>
<td>1.5</td>
<td>0.1</td>
</tr>
<tr>
<td>Under 65</td>
<td>0.7</td>
<td>1.4</td>
<td>0.1</td>
</tr>
<tr>
<td>65 and over</td>
<td>1.1</td>
<td>2.0</td>
<td>0.6</td>
</tr>
<tr>
<td>All ages(IARC world std)</td>
<td>0.6</td>
<td>1.1</td>
<td>0.1</td>
</tr>
</tbody>
</table>

AGE-SPECIFIC RATES, 1998-2002

<table>
<thead>
<tr>
<th>AGE AT DIAGNOSIS:</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10-14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15-19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20-24</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25-29</td>
<td>0.7</td>
<td>1.4</td>
<td></td>
</tr>
<tr>
<td>30-34</td>
<td>1.5</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>35-39</td>
<td>1.9</td>
<td>3.8</td>
<td></td>
</tr>
<tr>
<td>40-44</td>
<td>1.7</td>
<td>3.2</td>
<td></td>
</tr>
<tr>
<td>45-49</td>
<td>1.1</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>50-54</td>
<td>0.8</td>
<td>1.6</td>
<td></td>
</tr>
<tr>
<td>55-59</td>
<td>0.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>60-64</td>
<td>0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-69</td>
<td>0.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>70-74</td>
<td>0.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>75-79</td>
<td>1.1</td>
<td>1.8</td>
<td></td>
</tr>
<tr>
<td>80-84</td>
<td>1.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td>2.7</td>
<td>5.2</td>
<td></td>
</tr>
</tbody>
</table>

* SEER 9 areas. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.

* SEER 9 areas: Rates are per 100,000 and are age-adjusted to the IARC world standard population.

* Statistic not shown. Rate based on less than 25 cases for the time interval.
Table X-5
KAPOSI SARCOMA (Invasive)

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

<table>
<thead>
<tr>
<th></th>
<th>All Races</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td></td>
</tr>
<tr>
<td>5-YR RELATIVE SURVIVAL RATES</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YEAR OF DIAGNOSIS:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1960-1963</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1970-1973</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1974-1976</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1977-1979</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1980-1982</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1983-1985</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1986-1988</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1989-1991</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1992-1994</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1995-2001</td>
<td>45.2d</td>
<td>44.8d</td>
<td>52.7e</td>
<td></td>
</tr>
</tbody>
</table>

5-YR PERIOD SURVIVAL RATESbc

| YEAR OF DIAGNOSIS:                                  |           |                  |                  |                  |
| 1995-2001                                           | 54.3      | 53.8             | 58.1             |                  |

5-YR RELATIVE SURVIVAL RATES, 1995-2001b

| AGE AT DIAGNOSIS:                                  |           |                  |                  |                  |
| <45                                               | 41.3      | 41.6             | 18.0f            |                  |
| 45-54                                             | 45.7      | 45.9             |                  |                  |
| 55-64                                             | 60.0e     | 58.2e            |                  |                  |
| 65-74                                             | 78.8e     | 78.2e            |                  |                  |
| 75+                                               | 79.8e     | 85.6f            | 71.5f            |                  |
| Under 65                                          | 43.0      | 43.1             | 34.0e            |                  |
| 65 and over                                       | 78.9e     | 82.5g            | 70.5f            |                  |

---

a Rates are based on End Results data from a series of hospital registries and one population-based registry.
b Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).c Rates are based on follow-up of patients into 2002.d Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (1999-2001: 0-1 year survival), (1998-2000: 1-2 year survival), (1997-1999: 2-3 year survival), (1996-1998: 3-4 year survival), (1995-1997: 4-5 years survival).e The difference in rates between 1974-1976 and 1995-2001 is statistically significant (p<.05).f The standard error of the survival rate is between 5 and 10 percentage points. g The standard error of the survival rate is greater than 10 percentage points. h Statistic could not be calculated.
### Table X-6
**KAPOSI SARCOMA (Invasive)**

**SURVIVAL RATES**

By Year of Diagnosis

**All Races, Males and Females**

**Year of Diagnosis**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1-year</td>
<td>94.9</td>
<td>66.8</td>
<td>51.7</td>
<td>55.7</td>
<td>64.2</td>
<td>62.8</td>
<td>62.0</td>
<td>62.8</td>
</tr>
<tr>
<td>2-year</td>
<td>89.4</td>
<td>44.4</td>
<td>27.2</td>
<td>31.7</td>
<td>33.0</td>
<td>34.0</td>
<td>34.9</td>
<td>33.6</td>
</tr>
<tr>
<td>3-year</td>
<td>88.6</td>
<td>35.0</td>
<td>21.1</td>
<td>19.2</td>
<td>22.4</td>
<td>18.7</td>
<td>19.5</td>
<td>19.5</td>
</tr>
<tr>
<td>4-year</td>
<td>84.0</td>
<td>30.3</td>
<td>15.8</td>
<td>13.4</td>
<td>13.2</td>
<td>13.0</td>
<td>14.1</td>
<td>10.7</td>
</tr>
<tr>
<td>5-year</td>
<td>84.0</td>
<td>26.1</td>
<td>12.7</td>
<td>10.3</td>
<td>11.0</td>
<td>8.9</td>
<td>8.9</td>
<td>9.4</td>
</tr>
<tr>
<td>6-year</td>
<td>79.4</td>
<td>22.0</td>
<td>11.2</td>
<td>8.7</td>
<td>9.5</td>
<td>7.5</td>
<td>6.7</td>
<td>7.3</td>
</tr>
<tr>
<td>7-year</td>
<td>77.8</td>
<td>20.6</td>
<td>9.8</td>
<td>6.5</td>
<td>8.2</td>
<td>6.3</td>
<td>6.0</td>
<td>6.7</td>
</tr>
<tr>
<td>8-year</td>
<td>77.8</td>
<td>17.5</td>
<td>8.1</td>
<td>5.8</td>
<td>6.7</td>
<td>5.4</td>
<td>5.3</td>
<td>6.0</td>
</tr>
<tr>
<td>9-year</td>
<td>77.8</td>
<td>15.8</td>
<td>7.5</td>
<td>4.5</td>
<td>5.3</td>
<td>5.1</td>
<td>4.9</td>
<td>5.7</td>
</tr>
<tr>
<td>10-year</td>
<td>77.8</td>
<td>13.7</td>
<td>6.9</td>
<td>4.2</td>
<td>4.5</td>
<td>4.8</td>
<td>4.8</td>
<td>5.6</td>
</tr>
<tr>
<td>11-year</td>
<td>77.5</td>
<td>12.1</td>
<td>6.1</td>
<td>3.7</td>
<td>4.1</td>
<td>4.7</td>
<td>4.5</td>
<td>5.3</td>
</tr>
<tr>
<td>12-year</td>
<td>77.5</td>
<td>11.6</td>
<td>5.3</td>
<td>3.4</td>
<td>4.0</td>
<td>4.7</td>
<td>4.4</td>
<td>5.3</td>
</tr>
<tr>
<td>13-year</td>
<td>77.5</td>
<td>10.7</td>
<td>4.7</td>
<td>3.2</td>
<td>3.6</td>
<td>4.1</td>
<td>4.1</td>
<td></td>
</tr>
<tr>
<td>14-year</td>
<td>77.5</td>
<td>10.5</td>
<td>4.3</td>
<td>3.1</td>
<td>3.4</td>
<td>3.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15-year</td>
<td>77.5</td>
<td>9.9</td>
<td>4.1</td>
<td>3.1</td>
<td>3.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16-year</td>
<td>77.5</td>
<td>9.3</td>
<td>4.1</td>
<td>3.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17-year</td>
<td>77.5</td>
<td>8.7</td>
<td>3.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-year</td>
<td>77.5</td>
<td>7.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19-year</td>
<td>77.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20-year</td>
<td>77.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

*a* Survival rates are relative rates expressed as percents.

*b* Rates are from the SEER 9 areas.
Table X-7
KAPOSI SARCOMA (Invasive)

SURVIVAL RATES*  
By Year of Diagnosis  
All Races, Males  
Year of Diagnosis

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1-year</td>
<td>95.1</td>
<td>65.0</td>
<td>50.6</td>
<td>55.0</td>
<td>63.9</td>
<td>62.6</td>
<td>62.3</td>
<td>61.7</td>
<td>62.5</td>
<td>62.6</td>
<td>58.9</td>
<td>55.0</td>
<td>61.4</td>
<td>68.5</td>
<td>72.5</td>
<td>72.2</td>
<td>75.6</td>
<td>72.6</td>
<td>78.6</td>
</tr>
<tr>
<td>2-year</td>
<td>89.4</td>
<td>41.7</td>
<td>25.4</td>
<td>31.1</td>
<td>38.0</td>
<td>33.4</td>
<td>34.6</td>
<td>33.3</td>
<td>29.8</td>
<td>27.8</td>
<td>29.6</td>
<td>26.8</td>
<td>45.2</td>
<td>58.8</td>
<td>62.7</td>
<td>62.5</td>
<td>64.2</td>
<td>64.3</td>
<td></td>
</tr>
<tr>
<td>3-year</td>
<td>87.7</td>
<td>32.5</td>
<td>19.2</td>
<td>18.5</td>
<td>21.5</td>
<td>19.2</td>
<td>19.9</td>
<td>18.9</td>
<td>14.5</td>
<td>15.6</td>
<td>18.8</td>
<td>20.0</td>
<td>41.2</td>
<td>53.1</td>
<td>58.6</td>
<td>58.2</td>
<td>60.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4-year</td>
<td>84.2</td>
<td>27.7</td>
<td>14.0</td>
<td>12.6</td>
<td>14.2</td>
<td>11.7</td>
<td>12.6</td>
<td>13.6</td>
<td>9.8</td>
<td>10.2</td>
<td>14.5</td>
<td>17.5</td>
<td>36.9</td>
<td>49.9</td>
<td>54.3</td>
<td>54.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-year</td>
<td>84.2</td>
<td>23.8</td>
<td>10.7</td>
<td>9.5</td>
<td>10.1</td>
<td>8.2</td>
<td>8.7</td>
<td>9.0</td>
<td>7.5</td>
<td>8.1</td>
<td>12.9</td>
<td>16.3</td>
<td>34.0</td>
<td>47.0</td>
<td>52.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-year</td>
<td>76.7</td>
<td>19.8</td>
<td>9.2</td>
<td>8.0</td>
<td>8.6</td>
<td>8.6</td>
<td>6.8</td>
<td>6.9</td>
<td>6.5</td>
<td>7.5</td>
<td>12.4</td>
<td>15.2</td>
<td>33.4</td>
<td>44.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7-year</td>
<td>75.9</td>
<td>18.2</td>
<td>8.0</td>
<td>6.1</td>
<td>7.2</td>
<td>5.7</td>
<td>5.8</td>
<td>6.3</td>
<td>6.0</td>
<td>6.7</td>
<td>11.8</td>
<td>14.0</td>
<td>31.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8-year</td>
<td>75.9</td>
<td>15.7</td>
<td>6.3</td>
<td>5.4</td>
<td>6.2</td>
<td>4.9</td>
<td>5.1</td>
<td>5.7</td>
<td>5.6</td>
<td>6.7</td>
<td>11.1</td>
<td>13.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9-year</td>
<td>75.9</td>
<td>14.2</td>
<td>5.9</td>
<td>4.1</td>
<td>4.9</td>
<td>4.6</td>
<td>4.6</td>
<td>5.4</td>
<td>5.0</td>
<td>6.6</td>
<td>10.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10-year</td>
<td>75.9</td>
<td>12.2</td>
<td>5.5</td>
<td>3.8</td>
<td>4.3</td>
<td>4.4</td>
<td>4.6</td>
<td>5.3</td>
<td>4.8</td>
<td>6.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11-year</td>
<td>72.0</td>
<td>10.7</td>
<td>4.9</td>
<td>3.4</td>
<td>4.1</td>
<td>4.3</td>
<td>4.4</td>
<td>5.1</td>
<td>4.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-year</td>
<td>72.0</td>
<td>10.3</td>
<td>4.5</td>
<td>3.1</td>
<td>4.0</td>
<td>4.3</td>
<td>4.2</td>
<td>5.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13-year</td>
<td>72.0</td>
<td>9.5</td>
<td>4.1</td>
<td>2.9</td>
<td>3.6</td>
<td>3.8</td>
<td>4.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14-year</td>
<td>72.0</td>
<td>9.3</td>
<td>4.1</td>
<td>2.8</td>
<td>3.5</td>
<td>3.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15-year</td>
<td>72.0</td>
<td>8.5</td>
<td>3.9</td>
<td>2.8</td>
<td>3.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16-year</td>
<td>72.0</td>
<td>8.2</td>
<td>3.9</td>
<td>2.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17-year</td>
<td>72.0</td>
<td>8.0</td>
<td>3.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-year</td>
<td>72.0</td>
<td>7.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19-year</td>
<td>72.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20-year</td>
<td>72.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Survival rates are relative rates expressed as percents.

b Rates are from the SEER 9 areas.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1-year</td>
<td>93.3</td>
<td>92.1</td>
<td>85.1</td>
<td>100.0</td>
<td>79.3</td>
<td>80.8</td>
<td>66.9</td>
<td>77.6</td>
<td>89.9</td>
<td>74.7</td>
<td>70.9</td>
<td>82.3</td>
<td>88.0</td>
<td>79.5</td>
<td>70.6</td>
<td>86.8</td>
<td>65.8</td>
<td>75.6</td>
<td>87.0</td>
</tr>
<tr>
<td>2-year</td>
<td>89.4</td>
<td>87.2</td>
<td>85.1</td>
<td>77.4</td>
<td>79.3</td>
<td>80.8</td>
<td>54.2</td>
<td>50.4</td>
<td>78.9</td>
<td>53.5</td>
<td>70.9</td>
<td>56.5</td>
<td>86.1</td>
<td>79.5</td>
<td>65.0</td>
<td>86.8</td>
<td>57.2</td>
<td>75.6</td>
<td></td>
</tr>
<tr>
<td>3-year</td>
<td>89.4</td>
<td>77.6</td>
<td>85.1</td>
<td>69.6</td>
<td>79.3</td>
<td>78.6</td>
<td>40.7</td>
<td>50.4</td>
<td>73.7</td>
<td>43.2</td>
<td>50.7</td>
<td>48.3</td>
<td>73.8</td>
<td>66.9</td>
<td>65.0</td>
<td>86.8</td>
<td>49.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4-year</td>
<td>83.3</td>
<td>74.6</td>
<td>84.9</td>
<td>69.6</td>
<td>79.3</td>
<td>75.5</td>
<td>40.7</td>
<td>43.4</td>
<td>73.7</td>
<td>31.9</td>
<td>50.7</td>
<td>43.6</td>
<td>68.5</td>
<td>66.9</td>
<td>63.5</td>
<td>86.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-year</td>
<td>81.1</td>
<td>69.7</td>
<td>84.9</td>
<td>69.6</td>
<td>79.3</td>
<td>69.0</td>
<td>37.4</td>
<td>40.1</td>
<td>71.2</td>
<td>31.9</td>
<td>50.7</td>
<td>43.6</td>
<td>49.4</td>
<td>57.6</td>
<td>46.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-year</td>
<td>81.1</td>
<td>65.9</td>
<td>84.9</td>
<td>69.2</td>
<td>79.3</td>
<td>69.0</td>
<td>29.5</td>
<td>34.6</td>
<td>71.2</td>
<td>26.9</td>
<td>43.2</td>
<td>35.2</td>
<td>49.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7-year</td>
<td>81.1</td>
<td>65.9</td>
<td>84.9</td>
<td>45.6</td>
<td>79.3</td>
<td>65.0</td>
<td>29.5</td>
<td>34.6</td>
<td>71.2</td>
<td>26.9</td>
<td>43.2</td>
<td>35.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8-year</td>
<td>81.1</td>
<td>60.5</td>
<td>84.9</td>
<td>45.6</td>
<td>66.0</td>
<td>57.3</td>
<td>29.5</td>
<td>33.3</td>
<td>71.2</td>
<td>22.0</td>
<td>43.2</td>
<td>35.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9-year</td>
<td>81.1</td>
<td>58.7</td>
<td>84.9</td>
<td>45.6</td>
<td>53.2</td>
<td>57.3</td>
<td>29.5</td>
<td>33.3</td>
<td>71.2</td>
<td>22.0</td>
<td>37.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10-year</td>
<td>81.1</td>
<td>53.9</td>
<td>84.9</td>
<td>45.6</td>
<td>19.1</td>
<td>52.4</td>
<td>29.5</td>
<td>27.0</td>
<td>71.2</td>
<td>22.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11-year</td>
<td>81.1</td>
<td>51.9</td>
<td>82.1</td>
<td>40.5</td>
<td>0.0</td>
<td>52.4</td>
<td>25.6</td>
<td>19.7</td>
<td>71.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-year</td>
<td>81.1</td>
<td>51.9</td>
<td>61.9</td>
<td>40.5</td>
<td>0.0</td>
<td>44.2</td>
<td>25.6</td>
<td>19.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13-year</td>
<td>81.1</td>
<td>51.9</td>
<td>50.2</td>
<td>40.5</td>
<td>0.0</td>
<td>44.2</td>
<td>14.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14-year</td>
<td>81.1</td>
<td>51.9</td>
<td>19.2</td>
<td>40.5</td>
<td>0.0</td>
<td>34.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15-year</td>
<td>81.1</td>
<td>51.9</td>
<td>19.2</td>
<td>40.5</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16-year</td>
<td>81.1</td>
<td>51.9</td>
<td>19.2</td>
<td>40.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17-year</td>
<td>81.1</td>
<td>48.5</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-year</td>
<td>81.1</td>
<td>22.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19-year</td>
<td>81.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20-year</td>
<td>81.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Survival rates are relative rates expressed as percents.

b Rates are from the SEER 9 areas.
### Table X-9

**KAPOSI SARCOMA**

Percent Diagnosed With Cancer In 10, 20 and 30 Years and In Remaining Lifetime, Given Cancer Free At Current Age By Race and Sex

Lifetime Risk (Percent) of Being Diagnosed (13 SEER Areas) With Cancer 2000-2002

<table>
<thead>
<tr>
<th>Current Age</th>
<th>All Races</th>
<th></th>
<th></th>
<th>Whites</th>
<th></th>
<th></th>
<th>Blacks</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+10 yrs</td>
<td>+20 yrs</td>
<td>+30 yrs</td>
<td>Eventually</td>
<td>+10 yrs</td>
<td>+20 yrs</td>
<td>+30 yrs</td>
<td>Eventually</td>
<td>+10 yrs</td>
</tr>
<tr>
<td>0</td>
<td>0.00</td>
<td>0.00</td>
<td>0.01</td>
<td>0.12</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.02</td>
<td>0.00</td>
</tr>
<tr>
<td>10</td>
<td>0.00</td>
<td>0.01</td>
<td>0.04</td>
<td>0.12</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.02</td>
<td>0.00</td>
</tr>
<tr>
<td>20</td>
<td>0.01</td>
<td>0.04</td>
<td>0.07</td>
<td>0.12</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.02</td>
<td>0.00</td>
</tr>
<tr>
<td>30</td>
<td>0.03</td>
<td>0.07</td>
<td>0.08</td>
<td>0.11</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.02</td>
<td>0.00</td>
</tr>
<tr>
<td>40</td>
<td>0.03</td>
<td>0.04</td>
<td>0.05</td>
<td>0.08</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.02</td>
<td>0.00</td>
</tr>
<tr>
<td>50</td>
<td>0.01</td>
<td>0.02</td>
<td>0.03</td>
<td>0.05</td>
<td>0.00</td>
<td>0.00</td>
<td>0.01</td>
<td>0.02</td>
<td>0.00</td>
</tr>
<tr>
<td>60</td>
<td>0.01</td>
<td>0.02</td>
<td>0.03</td>
<td>0.04</td>
<td>0.00</td>
<td>0.01</td>
<td>0.01</td>
<td>0.02</td>
<td>0.00</td>
</tr>
</tbody>
</table>

**Lifetime Risk of Being Diagnosed**
- All Races: 0.12%
- Whites: 0.10%
- Blacks: 0.23%
- Lifetime Risk of Being Diagnosed = 0.02%
### Table X-10

**KAPOSI SARCOMA**

<table>
<thead>
<tr>
<th>SEER INCIDENCE</th>
<th>AGE-ADJUSTED RATES AND TRENDS&lt;sup&gt;a&lt;/sup&gt;</th>
<th>By Race/Ethnicity and Sex</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Rate 1998-2002</td>
<td>Trend 1992-2002</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rate per 100,000 persons</th>
<th>APC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td><strong>Males</strong></td>
</tr>
<tr>
<td>All Races</td>
<td>0.9</td>
</tr>
<tr>
<td>White</td>
<td>0.8</td>
</tr>
<tr>
<td>White Hispanic&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.2</td>
</tr>
<tr>
<td>White Non-Hispanic&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.7</td>
</tr>
<tr>
<td>Black</td>
<td>1.8</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>0.2</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>-</td>
</tr>
<tr>
<td>Hispanic&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.2</td>
</tr>
</tbody>
</table>

---

<sup>a</sup> The APC is the Annual Percent Change over the time interval.

<sup>b</sup> Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.


<sup>d</sup> Incidence data are from the 13 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

<sup>e</sup> Hispanic and Non-Hispanic are not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics do not include cases from Detroit, Hawaii, Alaska Native Registry and Rural Georgia.

<sup>f</sup> The APC is significantly different from zero (p<.05).
Table X-11
KAPOSISARCOMA (Invasive)

AGE-ADJUSTED SEER INCIDENCE RATES
By Registry, Race and Sex

<table>
<thead>
<tr>
<th>SEER INCIDENCE RATES*</th>
<th>1998-2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>By Registry, Race and Sex</td>
<td></td>
</tr>
<tr>
<td>All Races</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td></td>
</tr>
<tr>
<td>Whites</td>
<td>Total</td>
</tr>
<tr>
<td>Total</td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td></td>
</tr>
<tr>
<td>Blacks</td>
<td>Total</td>
</tr>
<tr>
<td>Total</td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td></td>
</tr>
</tbody>
</table>

**Statistics could not be calculated or populations are inadequate.**

---

* Incidence rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

* The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta. The SEER 11 areas comprise the SEER 9 areas plus San Jose-Monterey and Los Angeles. The SEER 13 areas comprise the SEER 11 areas plus the Alaska Native Registry and Rural Georgia.
### Table X-12

**KAPOSI'S SARCOMA (Invasive)**

**Estimated United States Cancer Prevalence Counts** on January 1, 2002

*By Race/Ethnicity, Sex and Years Since Diagnosis*

<table>
<thead>
<tr>
<th>Years Since Diagnosis</th>
<th>0 to &lt;5</th>
<th>5 to &lt;10</th>
<th>10 to &lt;15</th>
<th>15 to &lt;20</th>
<th>20 to &lt;25</th>
<th>0 to &lt;12*</th>
<th>0 to &lt;27*</th>
<th>&gt;=27f</th>
<th>Completeg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Race/Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Races*</td>
<td>7,140</td>
<td>8,705</td>
<td>2,599</td>
<td>822</td>
<td>288</td>
<td>17,179</td>
<td>19,711</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Males</td>
<td>6,545</td>
<td>8,354</td>
<td>2,400</td>
<td>743</td>
<td>196</td>
<td>16,079</td>
<td>18,332</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Females</td>
<td>595</td>
<td>351</td>
<td>193</td>
<td>79</td>
<td>92</td>
<td>1,100</td>
<td>1,379</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Whiteb</td>
<td>4,912</td>
<td>7,144</td>
<td>2,096</td>
<td>671</td>
<td>253</td>
<td>13,124</td>
<td>15,199</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Males</td>
<td>4,484</td>
<td>6,882</td>
<td>1,945</td>
<td>603</td>
<td>161</td>
<td>12,316</td>
<td>14,170</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Females</td>
<td>428</td>
<td>262</td>
<td>151</td>
<td>68</td>
<td>92</td>
<td>808</td>
<td>1,029</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Blackb</td>
<td>1,751</td>
<td>1,109</td>
<td>247</td>
<td>93</td>
<td>12</td>
<td>2,992</td>
<td>3,205</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Males</td>
<td>1,633</td>
<td>1,035</td>
<td>210</td>
<td>93</td>
<td>12</td>
<td>2,776</td>
<td>2,976</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Females</td>
<td>0</td>
<td>118</td>
<td>74</td>
<td>37</td>
<td>0</td>
<td>216</td>
<td>229</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Asian/Pacific Islanderc</td>
<td>89</td>
<td>97</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>192</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Males</td>
<td>85</td>
<td>95</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>185</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Females</td>
<td>4</td>
<td>2</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>7</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Hispanicf</td>
<td>1,128</td>
<td>1,239</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>2,512</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Males</td>
<td>1,051</td>
<td>1,206</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>2,387</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Females</td>
<td>77</td>
<td>33</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>125</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

---

**Estimated prevalence percent** on January 1, 2002, of the SEER 11 population diagnosed in the previous 10 years

*By Age at Prevalence, Race/Ethnicity and Sex*

<table>
<thead>
<tr>
<th>Age at Prevalence</th>
<th>All Ages</th>
<th>0-9</th>
<th>10-19</th>
<th>20-29</th>
<th>30-39</th>
<th>40-49</th>
<th>50-59</th>
<th>60-69</th>
<th>70-79</th>
<th>80+</th>
<th>All Ages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Race/Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Races*</td>
<td>0.0064%</td>
<td>-</td>
<td>-</td>
<td>0.0008%</td>
<td>0.0107%</td>
<td>0.0170%</td>
<td>0.0093%</td>
<td>0.0047%</td>
<td>0.0055%</td>
<td>0.0116%</td>
<td>0.0065%</td>
</tr>
<tr>
<td>Males</td>
<td>0.0124%</td>
<td>-</td>
<td>-</td>
<td>0.0014%</td>
<td>0.0206%</td>
<td>0.0333%</td>
<td>0.0186%</td>
<td>0.0089%</td>
<td>0.0106%</td>
<td>0.0209%</td>
<td>0.0126%</td>
</tr>
<tr>
<td>Females</td>
<td>0.0006%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.0005%</td>
<td>0.0005%</td>
<td>0.0005%</td>
<td>0.0009%</td>
<td>0.0017%</td>
<td>0.0065%</td>
<td>0.0006%</td>
</tr>
<tr>
<td>Whiteb</td>
<td>0.0065%</td>
<td>-</td>
<td>-</td>
<td>0.0005%</td>
<td>0.0105%</td>
<td>0.0168%</td>
<td>0.0095%</td>
<td>0.0048%</td>
<td>0.0058%</td>
<td>0.0119%</td>
<td>0.0064%</td>
</tr>
<tr>
<td>Males</td>
<td>0.0123%</td>
<td>-</td>
<td>-</td>
<td>0.0009%</td>
<td>0.0199%</td>
<td>0.0330%</td>
<td>0.0188%</td>
<td>0.0091%</td>
<td>0.0110%</td>
<td>0.0219%</td>
<td>0.0125%</td>
</tr>
<tr>
<td>Females</td>
<td>0.0006%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.0005%</td>
<td>0.0003%</td>
<td>0.0004%</td>
<td>0.0008%</td>
<td>0.0019%</td>
<td>0.0065%</td>
<td>0.0006%</td>
</tr>
<tr>
<td>Blackb</td>
<td>0.0086%</td>
<td>-</td>
<td>-</td>
<td>0.0026%</td>
<td>0.0177%</td>
<td>0.0245%</td>
<td>0.0111%</td>
<td>0.0051%</td>
<td>-</td>
<td>0.0114%</td>
<td>0.0090%</td>
</tr>
<tr>
<td>Males</td>
<td>0.0017%</td>
<td>-</td>
<td>-</td>
<td>0.0054%</td>
<td>0.0370%</td>
<td>0.0509%</td>
<td>0.0228%</td>
<td>0.0096%</td>
<td>-</td>
<td>-</td>
<td>0.0181%</td>
</tr>
<tr>
<td>Females</td>
<td>0.0008%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.0014%</td>
<td>0.0004%</td>
<td>0.0026%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.0010%</td>
</tr>
<tr>
<td>Asian/Pacific Islanderf</td>
<td>0.0016%</td>
<td>-</td>
<td>-</td>
<td>0.0018%</td>
<td>0.0044%</td>
<td>0.0026%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.0048%</td>
<td>0.0016%</td>
</tr>
<tr>
<td>Males</td>
<td>0.0031%</td>
<td>-</td>
<td>-</td>
<td>0.0037%</td>
<td>0.0092%</td>
<td>0.0051%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.0032%</td>
</tr>
<tr>
<td>Females</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hispanicf</td>
<td>0.0063%</td>
<td>-</td>
<td>-</td>
<td>0.0007%</td>
<td>0.0135%</td>
<td>0.0195%</td>
<td>0.0115%</td>
<td>0.0069%</td>
<td>0.0083%</td>
<td>0.0257%</td>
<td>0.0084%</td>
</tr>
<tr>
<td>Males</td>
<td>0.0017%</td>
<td>-</td>
<td>-</td>
<td>0.0014%</td>
<td>0.0246%</td>
<td>0.0382%</td>
<td>0.0231%</td>
<td>0.0129%</td>
<td>0.0187%</td>
<td>0.0362%</td>
<td>0.0158%</td>
</tr>
<tr>
<td>Females</td>
<td>0.0006%</td>
<td>-</td>
<td>-</td>
<td>0.0008%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.0199%</td>
<td>0.0011%</td>
</tr>
</tbody>
</table>

---

*a* US 2002 cancer prevalence counts are based on 2002 cancer prevalence proportions from the SEER registries and 1/1/2002 US population estimates based on the average of 2001 and 2002 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

b,c,d, e Statistics based on 

b SEER 9 Areas 

c SEER 11 Areas and Rural Georgia 

ed SEER 11 Areas excluding Hawaii and Detroit.


f Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

f,g,h,i Cases diagnosed more than 27 years ago were estimated using the completeness index method (Capoccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <27 and >=27. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

* Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.
All Cancer Sites vs Kaposi Sarcoma
SEER Incidence Rates, 1975-2002
Males, Ages 20-54

All SEER excluding San Francisco/Oakland Males, Ages 20-54 1975-2002

San Francisco/Oakland Males, Ages 20-54 1975-2002

San Francisco County/City Males, Ages 20-54 1975-2002

Rate per 100,000

Kaposi Sarcoma*

Colorectal

Lung & Bronchus

Non-Hodgkin Lymphoma

Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

*Kaposi sarcoma excluded from colorectal, lung & bronchus, and non-hodgkin lymphoma.